Zealand Pharma Announces Financial Results for the First Nine Months of 2026
Company announcement – No. 56 / 2026 Zealand Pharma Announces Financial Results for the First Nine Months of 2026Advancing at pace towards Metabolic Frontier 2030: petrelintide in Phase 3, survodutide moving towards regulatory filings, positive CHMP opinion for ZeydovioTM, and new modalities for next wave Announced positive topline results from Phase 2 ZUPREME-2 trial with petrelintide and initiated a registrational Phase 3 program, marking a defining step toward establishing petrelintide as a future first-choice therapy for people living with overweight or obesity. Boehringer Ingelheim presented positive results from the SYNCHRONIZETM-2 and SYNCHRONIZETM-CVOT trials with survodutide, dem